## LH: Labcorp Holdings Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -4.2% below STRENGTH zone (4.0-10.0%); PEG 1.94 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-4.4% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($241.54)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Labcorp Takes Strategic Stake in RNA Diagnostics Firm**
- Source: AD HOC NEWS | 20251217T020827 | Somewhat-Bullish | Relevance: 100%
- Labcorp has made a strategic investment in Cofactor Genomics, partnering with Ascension Ventures, to accelerate the expansion of Cofactor's RNA-based diagnostic tools. This move aims to broaden the commercial reach of Cofactor's OncoPrism test, which predicts patient immune responses to immunotherapy. The investment aligns with Labcorp's initiative to enhance advanced diagnostics and precision medicine offerings.

**2. Will Strength in Biotechnology Unit Continue to Drive Danaher's Growth?**
- Source: TradingView â€” Track All Markets | 20251218T150802 | Somewhat-Bullish | Relevance: 63%
- Danaher Corporation's Biotechnology segment has shown strong growth, particularly in bioprocessing, driven by demand for consumables and monoclonal antibodies. Despite concerns about declining protein research equipment demand, the segment is expected to continue its steady performance due to recurring product demand. The article also compares Danaher's performance with peers like CVS Health and Labcorp and provides its valuation and estimates.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.00M) |
| Sells | 5 ($3.37M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 43.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (-0.7%)
- Blackrock Inc.: 9.8% (-10.3%)
- State Street Corpora: 4.6% (-0.8%)
- Victory Capital Mana: 3.2% (+20.0%)
- JPMORGAN CHASE & CO: 2.6% (+64.8%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-4.4% 5d) with bearish MACD, trend may be turning.
2. Insider selling cluster: $3.4M in recent transactions.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.94 elevated, pricing in significant growth expectations. Insider selling cluster ($3.4M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $20.9B |
| Beta | 0.96 |
| 52W Range | $209.38 - $293.72 |
| Short Interest | 4.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.94 |
| Forward P/E | 14.4 |
| Current P/E | 15.4 |
| YoY Growth | 7.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 0.2% to -4.2% (-4.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 8.2pp (needs >4.0% for momentum thesis). AM_20 at -3.9% indicates price below own 20MA trend. Underperforming sector by 4.2pp, stock-specific weakness. Below SMA200 (0.98x), long-term trend not supportive. MACD histogram bearish (-1.03), momentum weakening. Elevated volume (1.6x 20MA), institutional activity likely. OFD pattern: +SUH (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -4.22% (CS: 13) | Weak |
| RSI_14 | 35.4 | Neutral |
| MACD Histogram | -1.03 | Bearish |
| vs SMA20 | 0.961x | Below |
| vs SMA50 | 0.949x | Below |
| vs SMA200 | 0.979x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $252.02
- **Stop Loss:** $241.54 (4.2% risk)
- **Target:** $262.50 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 114
- **Position Value:** $28,730.28
- **Portfolio %:** 28.73%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-02-05 (Est: $3.94)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $4.14 | $4.18 | +1.0% |
| 2025Q2 | $4.18 | $4.35 | +4.1% |
| 2025Q1 | $3.73 | $3.84 | +2.8% |
| 2024Q4 | $3.39 | $3.45 | +1.7% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*